Werewolf Therapeutics, Inc. (NasdaqCM: HOWL)
Health Care · Biotechnology · US
$0.98
+0.04% today · -39.5% 1Y
Werewolf Therapeutics, Inc. (NasdaqCM: HOWL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $47.63M and employs 39 people.
Over the last twelve months the share price has lost 39.5%, trading between 0.27 and 1.83.
Tweenvest scores Werewolf Therapeutics, Inc. across four factors: quality 35/100, value 50/100. Its strongest factor is value.
HOWL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $47.63M
- Revenue (TTM)
- $21.00M
- P/E
- —
- EPS
- -0.75
- Dividend yield
- —
- Beta (5Y)
- 0.51
- 52-week high
- $1.83
- 52-week low
- $0.27
- Avg volume (3M)
- —
- Shares outstanding
- 48.60M
- Employees
- 39
- Next earnings
- —
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
- ISIN
- US95075A1079
- Founded
- 2017
- Listed since
- Apr 30, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Connect Biopharma Holdings LimitedNasdaqGM: CNTB | $48.27M | $0.77 | +0.58% |
| MiNK Therapeutics, Inc.NasdaqCM: INKT | $48.02M | $9.41 | -12.22% |
| HLB Panagene Co., Ltd.KOSDAQ: A046210 | $47.81M | ₩1,400.00 | -21.08% |
| Sangamo Therapeutics, Inc.OTCPK: SGMO.Q | $47.64M | $0.12 | +9.52% |
| Kalaris Therapeutics, Inc.NasdaqGM: KLRS | $47.61M | $2.00 | -15.25% |
| 2invest AGDB: 2INV | $47.49M | €7.68 | -3.52% |
| Norda ASAOTCNO: NORD | $47.08M | Nkr86.00 | — |
| TaiRx, Inc.TPEX: 6580 | $46.82M | NT$13.55 | -6.87% |
Figures last refreshed Oct 18, 2026.